Component,Publication Grant Number,Publication Doi,Publication Journal,Pubmed Id,Publication Title,Pubmed Url,Publication Year,Publication Keywords,Publication Authors,Publication Abstract,Publication Assay,Publication Tumor Type,Publication Tissue,Publication Dataset Alias,Publication Accessibility,PublicationView_id,Dataset View_id
PublicationView,CA271273,10.1016/j.cels.2023.03.004,Cell Syst,37080163,Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spaces,https://pubmed.ncbi.nlm.nih.gov/37080163,2023,"Spatial analysis, Tumor Microenvironment, Cell-cell Interactions, Transfer Learning, Single-cell Transcriptomics, Spatial Transcriptomics, Latent Space Factorization","Atul Deshpande, Melanie Loth, Dimitrios N Sidiropoulos, Shuming Zhang, Long Yuan, Alexander T F Bell, Qingfeng Zhu, Won Jin Ho, Cesar Santa-Maria, Daniele M Gilkes, Stephen R Williams, Cedric R Uytingco, Jennifer Chew, Andrej Hartnett, Zachary W Bent, Alexander V Favorov, Aleksander S Popel, Mark Yarchoan, Ashley Kiemen, Pei-Hsun Wu, Kohei Fujikura, Denis Wirtz, Laura D Wood, Lei Zheng, Elizabeth (Read more on Pubmed)",Recent advances in spatial transcriptomics (STs) enable gene expression measurements from a tissue sample while retaining its spatial context. This technology enables unprecedented in situ resolution of the regulatory pathways that underlie the heterogeneity in the tumor as well as the tumor microenvironment (TME). The direct characterization of cellular co-localization with spatial technologies f(Read more on Pubmed),Pending Annotation,Pending Annotation,Pending Annotation,,Restricted Access,37080163,37080163
PublicationView,CA271273,10.1158/2159-8290.cd-23-0277,Cancer Discov,37067199,Converging on a Cure: The Roads to Predictive Immunotherapy,https://pubmed.ncbi.nlm.nih.gov/37067199,2023,,"Genevieve L Stein-O'Brien, Dung T Le, Elizabeth M Jaffee, Elana J Fertig, Neeha Zaidi","Summary: Convergence science teams integrating clinical, biological, engineering, and computational expertise are inventing new forecast systems to monitor and predict evolutionary changes in tumor and immune interactions during early cancer progression and therapeutic response. The resulting methods should inform a new predictive medicine paradigm to select adaptive immunotherapeutic regimens per(Read more on Pubmed)",Pending Annotation,Pending Annotation,Pending Annotation,,Restricted Access,37067199,37067199
PublicationView,CA271273,10.4049/jimmunol.2200660,J Immunol,36947820,Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy,https://pubmed.ncbi.nlm.nih.gov/36947820,2023,,"Janelle M Montagne, Elizabeth M Jaffee, Elana J Fertig","Advances in cancer immunotherapy, particularly immune checkpoint inhibitors, have dramatically improved the prognosis for patients with metastatic melanoma and other previously incurable cancers. However, patients with pancreatic ductal adenocarcinoma (PDAC) generally do not respond to these therapies. PDAC is exceptionally difficult to treat because of its often late stage at diagnosis, modest mu(Read more on Pubmed)",Pending Annotation,Pending Annotation,Pending Annotation,,Restricted Access,36947820,36947820
